Clinical trials: Head and Neck Cancers- Squamous Cell
Head and Neck Cancer, Oral Complications
Paclitaxel and Radiation Therapy Plus Chemoprotection With Amifostine in Treating Patients With Stage III or Stage IV Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00003193
- Testing
- amifostine trihydrate, paclitaxel, conventional surgery
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- Massachusetts General Hospital
Head and Neck Squamous Cell Carcinoma
A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer
This study was designed to assess the safety and preliminary efficacy of duvelisib in combination with pembrolizumab in participants with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
- Trial name
- NCT04193293
- Testing
- Duvelisib, Pembrolizumab
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- SecuraBio
Head and Neck Cancer
SU5416 and Paclitaxel in Treating Patients With Recurrent, Locally Advanced or Metastatic Cancer of the Head and Neck
RATIONALE: SU5416 may stop the growth of head and neck cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00005647
- Testing
- paclitaxel, semaxanib
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Case Comprehensive Cancer Center
Squamous Cell Carcinoma of the Hypopharynx, Larynx Carcinoma
Docetaxel, Cisplatin (TP) + Radiation +/- Cetuximab in Larynx Carcinoma (CA)
The DeLOS II trial is a multicenter randomised phase II trial investigating a TP/5-Fluorouracil (TPF)-chemotherapy with or without cetuximab for Patients with only by laryngectomy operable carcinoma of the larynx/hypopharynx.
- Trial name
- DeLOS II (NCT00508664)
- Testing
- Radiation, Cetuximab, Docetaxel
- Where
- 27 sites in Austria, Germany
- Volunteers
- 180 people
- Sponsor
- ClinAssess
Head and Neck Carcinoma of Unknown Primary, Locally Recurrent Head and Neck Squamous Cell Carcinoma
Combining Immunotherapy Salvage Surgery & IORT Tx Persistent/Recurrent Head & Neck Cancer
This phase I trial is to find out the possible side effects of pembrolizumab and radiation therapy before and during surgery in treating patients with head and neck squamous cell cancer that remains despite treatment (persistent)…
- Conditions
- Head and Neck Carcinoma of Unknown Primary, Locally Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma
- Trial name
- NCT04754321
- Testing
- External Beam Radiation Therapy, Intraoperative Radiation Therapy, Pembrolizumab
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Esophageal Squamous Cell Carcinoma
Individualized Tumor-Informed CtDNA Analysis for Monitoring Postoperative Recurrence in ESCC (NEOCRTEC2401)
The goal of this observational study or is to explore the correlation between dynamic changes in postoperative circulating tumor DNA (ctDNA) and recurrence risk using a novel, tumor-informed ctDNA detection technique, thus laying…
- Trial name
- NCT06561178
- Testing
- molecular residual disease detection
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Sun Yat-Sen University Cancer Center
HNSCC, Radiotherapy
PD-1 Inhibitor Therapy Versus Radiotherapy in pCR Patients With Locally Advanced HNSCC After Neoadjuvant Immunochemotherapy
In patients with locally advanced head and neck squamous cell carcinoma undergoing standard surgical treatment after neoadjuvant immunochemotherapy, can PD-1 inhibitor therapy be used instead of adjuvant radiotherapy for both…
- Conditions
- HNSCC, Radiotherapy, PD-1
- Trial name
- HNC-SYSU-003 (NCT05980715)
- Testing
- PD-1inhibitor, concurrent chemoradiotherapy
- Where
- China
- Volunteers
- 324 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Esophageal Squamous Cell Carcinoma
Efficacy and Safety of Adebrelimab Combined With Chemoradiotherapy in Patients With Unresectable Locally Advanced or Postoperative Recurrent Esophageal Squamous Cell Carcinoma
This study was a multi-center, single-arm, open-label phase II clinical trial. Thirty patients with unresectable locally advanced or postoperative recurrent esophageal squamous cell carcinoma were treated with concurrent…
- Trial name
- NCT06885814
- Testing
- Adebrelimab: 1200 mg day1, Q3W, 3 times
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx
Gefitinib and Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III or Stage IV Head and Neck Cancer
This phase I trial is studying the side effects and best dose of gefitinib when given together with radiation therapy with or without cisplatin in treating patients with stage III or stage IV head and neck cancer.
- Conditions
- Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Oropharynx
- Trial name
- NCT00033449
- Testing
- gefitinib, radiation therapy, cisplatin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Carcinoma, Head and Neck
Mitomycin C in Patients With Incurable p16 Positive Oropharyngeal and p16 Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Resistant to Standard Therapies
No agent is known to have efficacy in patients with incurable HNSCC that progressed with prior platin, 5-FU, cetuximab and taxane. Herein lies the unmet need to be addressed by this trial.
- Trial name
- NCT02369458
- Testing
- Mitomycin-C, Pegfilgrastim
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Washington University School of Medicine
HNSCC
Artificial Intelligence in Functional Imaging for Individualized Treatment of Head and Neck Squamous Cell Carcinoma Patients
The two curative treatment modalities for patients with HNSCC - primary chemoradiation (CRT) or primary surgery (often combined with postoperative (C)RT) - are both associated with serious side effects for which reason further…
- Trial name
- KIVAL-KHT (NCT05192655)
- Testing
- Observation
- Where
- Germany
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Charite University, Berlin, Germany
Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)
CCR2 PET Imaging Head and Neck Squamous Cell Carcinoma
This is a prospective study to evaluate the sensitivity and specificity of Cu-64 DOTA-ECL1i PET/CT imaging to serve as a novel precision imaging tool for patients with head and neck squamous cell carcinoma (HNSCC).
- Conditions
- Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Head and Neck Squamous Cell Carcinoma HNSCC
- Trial name
- NCT07659678
- Testing
- 64Cu-DOTA-ECL1i
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Washington University School of Medicine
Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous
A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors
This trial will study ladiratuzumab vedotin (LV) alone and with pembrolizumab to find out if it works to treat different types of solid tumors. It will also find out what side effects may occur.
- Conditions
- Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous, Non-small Cell Lung Cancer, Non-squamous, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT04032704
- Testing
- ladiratuzumab vedotin, pembrolizumab
- Where
- 66 sites in United States, Australia and 4 more
- Volunteers
- 205 people
- Sponsor
- Seagen Inc.
Esophageal Squamous Cell Carcinoma Stage II, Esophageal Squamous Cell Carcinoma Stage III
Toripalimab Adjuvant Therapy in Subjects With Resected Esophageal Squamous Cell Carcinoma Who Achieved Pathological Complete Response (pCR)
The goal of this clinical trial is to assess the 1-year DFS rate of toripalimab adjuvant therapy in participants with resected esophageal squamous cell carcinoma (ESCC) who achieved pCR.
- Trial name
- NCT06903871
- Testing
- TORIPALIMAB INJECTION(JS001 )
- Where
- China
- Volunteers
- 190 people
- Sponsor
- Hebei Medical University Fourth Hospital
Carcinoma, Squamous Cell of Head and Neck, Tobacco Use Disorder
Smoking Tobacco Cessation Integrated Program of Patients Treated for the Head and the Neck Cancer
Head and neck squamous cell carcinomas (HNSCCs) arise in the mucosa of the upper aero-digestive tract. They are the 6th most prevalent type of cancer worldwide.
- Trial name
- INTENT (NCT03788785)
- Testing
- Experimental arm, Control arm
- Where
- 3 sites in France
- Volunteers
- 24 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable Disease
Immunotherapy has become the standard of care in different advanced malignancies. Its effectiveness in the palliative setting was demonstrated by several phase III trials.
- Conditions
- Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Melanoma, Urothelial Carcinoma
- Trial name
- ICONIC (NCT05229614)
- Testing
- Carbon Ion Therapy, Immunotherapy (Pembrolizumab)
- Where
- 4 sites in Germany, Italy
- Volunteers
- 27 people
- Sponsor
- CNAO National Center of Oncological Hadrontherapy
Head and Neck Neoplasm
Cetuximab as Induction Treatment in Head and Neck Squamous Cell Carcinoma (HNSCC)
The aim of the study is to investigate the efficacy and safety of cetuximab, docetaxel, cisplatin combination as induction therapy in locally advanced head and neck squamous cell carcinoma.
- Trial name
- NCT00623558
- Testing
- Cetuximab, Docetaxel, Cisplatin
- Where
- South Korea
- Volunteers
- 92 people
- Sponsor
- Seoul National University Hospital
Squamous Non-small-cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
A Study to Investigate ALE.P02 as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Selected CLDN1+ Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic, preliminary anti-tumor activity, and to determine the recommended Phase II dose (RP2D) of the ALE.P02 as a monotherapy or in…
- Conditions
- Squamous Non-small-cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma
- Trial name
- NCT06747585
- Testing
- ALE.P02, Pembrolizumab
- Where
- 41 sites in United States, France and 6 more
- Volunteers
- 235 people
- Sponsor
- Alentis Therapeutics AG
Head and Neck Squamous Cell Carcinoma, HNSCC
Phase 2 Trial of Maintenance Cemiplimab for Head and Neck Squamous Cell Carcinoma (HNSCC)
The purpose of this study is to evaluate the experimental immunotherapy agent cemiplimab-rwlc when given after completion of chemotherapy and radiation treatment and determine if it will improve progression free survival and cure…
- Conditions
- Head and Neck Squamous Cell Carcinoma, HNSCC, Squamous Cell Carcinoma of the Larynx, Squamous Cell Carcinoma of the Oral Cavity
- Trial name
- NCT04831450
- Testing
- Cemiplimab-Rwlc
- Sponsor
- University of Miami
Fatigue, Head and Neck Cancer
Insomnia in Patients Undergoing Chemotherapy and Radiation Therapy for Head and Neck Cancer
RATIONALE: Learning about insomnia and quality of life in patients undergoing chemotherapy and radiation therapy for cancer may help doctors learn about the effects of treatment and plan the best treatment.
- Conditions
- Fatigue, Head and Neck Cancer, Psychosocial Effects of Cancer and Its Treatment, Sleep Disorders
- Trial name
- NCT00616590
- Testing
- medical chart review, questionnaire administration, fatigue assessment and management
- Where
- 3 sites in United States
- Sponsor
- Vanderbilt University